

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA STRATEGIC HOLDINGS LIMITED

中策集團有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 235)

RE-DESIGNATION OF DIRECTOR AND CHANGE OF CHAIRMAN OF EXECUTIVE COMMITTEE AND INVESTMENT & CREDIT COMMITTEE

The Board announces that with effect from 1 April 2018, Dr. Or Ching Fai will be re-designated from an Executive Director to a Non-executive Director of the Company and will cease to be the Chairman of the Executive Committee and the Investment & Credit Committee of the Company. Mr. Sue Ka Lok, a member of the Executive Committee and the Investment & Credit Committee, will be appointed as the Chairman of the Executive Committee and the Investment & Credit Committee on 1 April 2018. Following the re-designation, Dr. Or will remain as the Chairman of the Board and the Chairman of the Nomination Committee of the Company.

The Board of Directors (the “**Board**”) of China Strategic Holdings Limited (the “**Company**”) hereby announces that with effect from 1 April 2018, Dr. Or Ching Fai (“**Dr. Or**”) will be re-designated from an Executive Director to a Non-executive Director of the Company as he needs to devote more time to his other business engagements and will cease to be the Chairman of the Executive Committee and the Investment & Credit Committee of the Company. Mr. Sue Ka Lok, a member of the Executive Committee and the Investment & Credit Committee, will be appointed as the Chairman of the Executive Committee and the Investment & Credit Committee on 1 April 2018. Following the re-designation, Dr. Or will remain as the Chairman of the Board and the Chairman of the Nomination Committee of the Company.

Dr. Or confirmed that he has no disagreement with the Board and there is no matter relating to his re-designation from an Executive Director to a Non-executive Director of the Company that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The biographical details of Dr. Or are set out below:

Aged 68, joined the Company as an Executive Director and the Chief Executive Officer in November 2009 and was appointed the Chairman in March 2012. He was the Chief Executive Officer of the Company until 18 January 2018. Dr. Or is the Chairman of the Nomination Committee, the Executive Committee and the Investment & Credit Committee. He is also a director of certain subsidiaries of the Company. Dr. Or graduated from The University of Hong Kong in 1972 and was conferred an Honorary Doctor of Social Science by the City University of Hong Kong in November 2014. Dr. Or is currently an independent non-executive director and the chairman of Esprit Holdings Limited (“**Esprit Holdings**”) (Hong Kong stock code: 330), and will be re-designated as an executive director of Esprit Holdings on 1 April 2018. Dr. Or is also an independent non-executive director of Chow Tai Fook Jewellery Group Limited (Hong Kong stock code: 1929), Industrial and Commercial Bank of China Limited (Hong Kong stock code: 1398), Regina Miracle International (Holdings) Limited (Hong Kong stock code: 2199) and Television Broadcasts Limited (Hong Kong stock code: 511). He was the former vice chairman and chief executive of Hang Seng Bank Limited (Hong Kong stock code: 11), the former chairman of Hang Seng Life Limited and a director of The Hongkong and Shanghai Banking Corporation Limited, Cathay Pacific Airways Limited (Hong Kong stock code: 293) and Hutchison Whampoa Limited (Hong Kong stock code: 13 (delisted)) until his retirement in May 2009. Dr. Or was also the former vice chairman and independent non-executive director of G-Resources Group Limited (Hong Kong stock code: 1051) until 30 June 2017 and the former deputy chairman and non-executive director of Aquis Entertainment Limited (stock code: ASX: AQS) (a company listed on the Australian Securities Exchange) until 31 December 2017. All of the aforementioned companies with Hong Kong stock code are/was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Save as disclosed above, Dr. Or has not held any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas for the last three years prior to the date of this announcement.

As at the date of this announcement, Dr. Or does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Or does not have any relationship with any directors, senior management, substantial Shareholders or controlling Shareholders.

Dr. Or has entered into a letter of appointment with the Company in relation to his position as a Non-executive Director of the Company with effect from 1 April 2018. According to the letter of appointment, Dr. Or's terms of service is fixed at a term of two years commencing from 1 April 2018 unless and until terminated by either party by giving to the other three months' prior notice in writing and shall determine upon expiry subject to renewal by mutual agreement between the Company and Dr. Or prior thereto and in compliance with the Rules Governing the Listing of Securities (the "**Listing Rules**") on the Stock Exchange. The directorship of Dr. Or is also subject to retirement by rotation and re-election pursuant to the Articles of Association of the Company. Dr. Or is entitled to receive a director's fee of HK\$2,150,000 per annum which has been recommended by the Remuneration Committee and approved by the Board based on his qualifications, experience, level of responsibilities undertaken, contribution to the Company and prevailing market conditions. The director's fee of Dr. Or will be subject to annual review by the Remuneration Committee and the Board.

Save as disclosed above, there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Listing Rules and there is no other matter relating to the re-designation of Dr. Or from an Executive Director to a Non-executive Director that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to thank Dr. Or for his valuable contribution to the Company during his tenure of office as an Executive Director and extend its warmest welcome to Dr. Or for his new role in the Company.

By Order of the Board
China Strategic Holdings Limited
Dr. Or Ching Fai
Chairman

Hong Kong, 21 March 2018

As at the date of this announcement, the Board comprises four Executive Directors, namely Dr. Or Ching Fai (Chairman), Mr. Sue Ka Lok (Chief Executive Officer), Ms. Lee Chun Yeung, Catherine and Mr. Chow Kam Wah; and three Independent Non-executive Directors, namely Ms. Ma Yin Fan, Mr. Chow Yu Chun, Alexander and Mr. Leung Hoi Ying.